Bill
Bill > HR6155
US HR6155
To amend the Biologics Price Competition and Innovation Act of 2009 to make improvements with respect to the transition of biological products, and for other purposes.
summary
Introduced
03/09/2020
03/09/2020
In Committee
03/09/2020
03/09/2020
Crossed Over
Passed
Dead
12/31/2020
12/31/2020
Introduced Session
116th Congress
Bill Summary
A BILL To amend the Biologics Price Competition and Innovation Act of 2009 to make improvements with respect to the transition of biological products, and for other purposes. 1
AI Summary
This bill amends the Biologics Price Competition and Innovation Act of 2009 to streamline the transition of biological products. Specifically, it allows the continued review of certain applications for biological products submitted under the Federal Food, Drug, and Cosmetic Act, even if the review continues past the transition date of March 23, 2020. The bill also deems certain insulin products approved under the Federal Food, Drug, and Cosmetic Act to be interchangeable biosimilar biological products licensed under the Public Health Service Act, providing a clearer regulatory pathway for these products.
Committee Categories
Business and Industry
Sponsors (1)
Last Action
Referred to the House Committee on Energy and Commerce. (on 03/09/2020)
Official Document
bill text
bill summary
Loading...
bill summary
Loading...
bill summary
| Document Type | Source Location |
|---|---|
| State Bill Page | https://www.congress.gov/bill/116th-congress/house-bill/6155/all-info |
| BillText | https://www.congress.gov/116/bills/hr6155/BILLS-116hr6155ih.pdf |
| Bill | https://www.congress.gov/116/bills/hr6155/BILLS-116hr6155ih.pdf.pdf |
Loading...